Terms ending in 2035
Every in-force patent on Genmab A/S's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,201,607 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,500,276 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,512,688 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,765,743 | Antibodies Binding Axl In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,115,227 | Formulation for Antibody and Drug Conjugate Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,589,150 | Antibodies Binding Axl In force · Medium confidence | Genmab A/S | In force | Medium confidence | |
| US 9,150,658 | Human Antibodies Against Tissue Factor and Methods of Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,407,501 | Humanized or Chimeric CD3 Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,465,006 | Humanized or Chimeric CD3 Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,544,220 | Bispecific Antibodies Against CD3 and CD20 In force · High confidence | Genmab A/S | In force | High confidence | |
| 1 more term end in 2035 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.